No “Constraining Situation” On gVascepa API Says Strides MD, Q3 Revenues Jump

gSuprep Likely To Be Launched In Q4

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business

Earnings Concept
Strides Reported A Strong Third Quarter And Expects Generic Vascepa To Add Momentum • Source: Shutterstock

Strides Pharma Science Limited founder and managing director Arun Kumar said he does not see a “constraining situation” for supplies of active pharmaceutical ingredients (API) to manufacture a generic to Amarin Corporation plc’s only commercialized product to date Vascepa (icosapent ethyl).

US marketing partner Amneal Pharmaceuticals, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip